Clinical Trials Logo

Filter by:
NCT ID: NCT00279760 Completed - Clinical trials for Rheumatoid Arthritis

Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

This randomized, double-blind, placebo controlled, parallel and multiple dose study provided safety, preliminary efficacy, and immunogenicity information about the use of BMS-188667 and BMS-224818 in subjects with RA

NCT ID: NCT00279045 Completed - Clinical trials for Diabetes Mellitus, Type 2

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

Start date: January 3, 2000
Phase: Phase 3
Study type: Interventional

The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.

NCT ID: NCT00276757 Completed - Clinical trials for Childhood Langerhans Cell Histiocytosis

Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis

Start date: April 2001
Phase: N/A
Study type: Interventional

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of Langerhans cell histiocytosis, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may be an effective treatment for Langerhans cell histiocytosis. PURPOSE: This randomized clinical trial is studying combination chemotherapy to see how well it works in treating young patients with Langerhans cell histiocytosis.

NCT ID: NCT00276692 Completed - Sarcoma Clinical Trials

Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma

Start date: August 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well irinotecan works in treating patients with newly diagnosed Ewing's sarcoma.

NCT ID: NCT00276679 Completed - Neuroblastoma Clinical Trials

Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma

Start date: April 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with high-risk relapsed or refractory neuroblastoma.

NCT ID: NCT00273988 Completed - Clinical trials for Acquired Immunodeficiency Syndrome

Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults

Start date: April 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study was to determine the effects of nevirapine treatment on the pharmacokinetics of methadone in HIV-1 infected, opioid-dependent adults who had been on a stable methadone maintenance therapy for at least five days prior to study entry.

NCT ID: NCT00273377 Completed - Clinical trials for Surgical Wound Infection

The Effects of Hypercapnia, Supplemental Oxygen, and Dexamethasone on Surgical Wound Infection

Start date: May 2002
Phase: Phase 3
Study type: Interventional

The investigators will test the hypotheses that mild hypercapnia and supplemental oxygen reduce wound infection risk in patients undergoing colon resection. The investigators will simultaneously test the hypothesis that low-dose dexamethasone (a common treatment for postoperative nausea and vomiting) does not increase infection risk.

NCT ID: NCT00272948 Completed - Clinical trials for Hepatic Veno-Occlusive Disease

Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide

VOD-DF
Start date: December 2005
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this trial is to evaluate whether the prophylactic use of Defibrotide (DF) in pediatric patients (age less than 18 years) undergoing stem cell transplantation and who are at high risk of developing hepatic Veno-occlusive Disease (VOD) will have an impact on the incidence and severity of the disease. Patients will be randomly assigned to one of two treatment arms: Those allocated to the Prophylactic Arm will receive the study drug (Defibrotide) from the day of conditioning onwards. Patients allocated to the Control Arm will receive the study drug (Defibrotide) from the day that VOD is diagnosed.

NCT ID: NCT00271154 Completed - Heart Failure Clinical Trials

REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE)

Start date: September 2004
Phase: N/A
Study type: Interventional

Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes. When there are changes in the heart beat sometimes an implantable heart device is used to control the rate and rhythm of the heart beat. The purpose of the REVERSE clinical trial is to determine whether pacing in both the left and right ventricles using Cardiac Resynchronization Therapy (CRT) can help slow the progression of heart failure in people who have mild or previous symptoms and poor heart pumping function. This kind of therapy has previously been shown to reduce symptoms and improve exercise capacity in people with more advanced forms of heart failure.

NCT ID: NCT00267943 Completed - Hypertension Clinical Trials

Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients

Start date: January 2006
Phase: Phase 3
Study type: Interventional

The primary objective is to assess the efficacy and safety of the fixed dose combination of telmisartan 80 mg + hydrochlorothiazide 25 mg (T80/H25) alone or in addition to other antihypertensive therapies during open-label, long-term treatment.